Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration

  • Authors:
    • Franco Ghezzo
    • Luigi Cesano
    • Barbara Mognetti
    • Eugenio Pesce
    • Elisa Pirro
    • Giovanna Corvetti
    • Giovanni N. Berta
    • Barbara Zingaro
    • Francesco Di Carlo
  • View Affiliations

  • Published online on: March 1, 2005     https://doi.org/10.3892/ijo.26.3.697
  • Pages: 697-702
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epidemiological data suggest that non-steroidal anti-inflammatory drugs prevent colon cancer. The evidence for other types of tumour is less conclusive, though animal and in vitro studies indicate that they may be effective against mammary cancer cells. We assessed the effect of dietary acetylsalicylic and salicylic acid against dimethylbenzanthracene-induced rat tumours. Tumour angiogenesis was also investigated to explore the mechanism responsible for salicylate effect. Mammary tumours were induced in female Sprague-Dawley rats fed with different amounts of acetylsalicylic and salicylic acid. Serum vascular endothelial growth factor concentrations were measured and vascularization of basement membrane proteins injected in vivo (Matrigel) was determined by evaluation of haemoglobin content to assess the extent to which angiogenesis was inhibited. Dimethylbenzanthracene-induced carcinogenesis was inhibited by both acids and there was a log-dose/response correlation between the tumour diameter and salicylate concentration. Salicylic acid seems more effective than acetylsalicylic acid. Vascular endothelial growth factor was less concentrated in treated animals than in the controls and so was Matrigel haemoglobin. The mechanism involved, however, is still uncertain, though concomitant inhibition of tumour angiogenesis may be an important component. The documented salicylate serum VEGF modulation is interesting also for presence of the flk-1 receptor in mammary tumour cells of our model. Although misoprostol is a prostaglandin analogous its concomitant administration did not compromise the salicylate anti-tumour effect.

Related Articles

Journal Cover

March 2005
Volume 26 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ghezzo F, Cesano L, Mognetti B, Pesce E, Pirro E, Corvetti G, Berta GN, Zingaro B and Di Carlo F: Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration. Int J Oncol 26: 697-702, 2005
APA
Ghezzo, F., Cesano, L., Mognetti, B., Pesce, E., Pirro, E., Corvetti, G. ... Di Carlo, F. (2005). Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration. International Journal of Oncology, 26, 697-702. https://doi.org/10.3892/ijo.26.3.697
MLA
Ghezzo, F., Cesano, L., Mognetti, B., Pesce, E., Pirro, E., Corvetti, G., Berta, G. N., Zingaro, B., Di Carlo, F."Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration". International Journal of Oncology 26.3 (2005): 697-702.
Chicago
Ghezzo, F., Cesano, L., Mognetti, B., Pesce, E., Pirro, E., Corvetti, G., Berta, G. N., Zingaro, B., Di Carlo, F."Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration". International Journal of Oncology 26, no. 3 (2005): 697-702. https://doi.org/10.3892/ijo.26.3.697